# US 2026/0224625 A1 · Compositions and methods for providing effects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224625 A1
- Document ID: US20260224625A1
- Status: Published application
- Kind: A1
- Application number: 19/271,474
- Filed: 2025-07-16
- Published: 2026-08-06
- Earliest claimed: 2020-01-31
- Assignees: G Tech Bio LLC
- Applicants: G Tech Bio LLC
- Inventors: Serhat Gumrukcu
- Web page: https://patentgrep.com/patent/US20260224625A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 31/015: carbocyclic
- A61K 31/255: of sulfoxy acids or sulfur analogues thereof
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 38/53: Ligases (6)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 39/00: General protective or antinoxious agents
- C12N 9/93: {Ligases (6)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Y 603/02002: Glutamate-cysteine ligase (6.3.2.2)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The disclosure relates to compositions and methods for providing chemoprotective effects to target cells.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

A method of treating a patient with cancer or HIV, the method comprising administering to the patient a pharmaceutical composition comprising a cell expressing heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function with a non-myeloablative or a myeloablative dose of a chemotherapeutic.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cell heterologously expresses GCLM.

### Claim 8 (depends on 6)

The method of claim 6, further comprising administering to the patient prior to, after, or simultaneously with the chemotherapeutic the cell expressing heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.

### Claim at position 5

9-14. (canceled)

### Claim 15 (depends on 6)

The method of claim 6, wherein the cells are stem cells or immune cells.

### Claim at position 7

16-19. (canceled)

### Claim 20 (depends on 6)

The method of claim 6, wherein the method further comprises administration to the patient busulfan and/or naphthalene.

### Claim 21 (depends on 6)

The method of claim 6, further comprising administering to the patient a myeloablative dose or a non-myeloablative dose of busulfan and/or naphthalene.

### Claim at position 10

22-73. (canceled)

### Claim 74

An isolated stem cell or an immune cell comprising heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function and at least one additional heterologously expressed molecule of interest.

### Claim 75 (depends on 74)

The cell of claim 74, wherein the cell comprises heterologous GCLM.

### Claim at position 13

76-78. (canceled)

### Claim 79 (depends on 24)

The cell of claim 24, wherein the cell is a T cell that further comprises a chimeric antigen receptor (CAR).

### Claim at position 15

80-83. (canceled)

### Claim 84 (depends on 74)

A pharmaceutical composition comprising the cell of claim 74 and a pharmaceutically acceptable buffer or excipient.

### Claim 85 (depends on 79)

A method of treating cancer m a patient, the method comprising administering busulfan to a patient, wherein the patient has been administered the cell of claim 79.

### Claim at position 18

86-90. (canceled)
